TNF-alpha, IL-6, IL-10 and Fatty Acids in Rheumatoid Arthritis Patients Receiving CDMARD and BDMARD Therapy

Overview

Journal Clin Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2022 Apr 25

PMID 35467309

Authors

Serdar Dogan

Gezmis Kimyon

Huseyin Ozkan

Filiz Kacmaz

Baran Camdeviren

Irem Karaaslan

Affiliations

Soon will be listed here.

Abstract

Objective: The present study aimed to examine the effects of cDMARD and bDMARD therapy on both gene expressions and protein levels of TNF-α, IL-6, IL-10 and fatty acid levels in patients with RA.

Method: Plasma TNF-α, IL-6, and IL-10 levels were examined by the ELISA method, while TNF-α, IL-6, and IL-10 gene expression levels were examined by RT-qPCR, and fatty acid levels were examined by GC/MS.

Results: IL-10 gene expression levels significantly increased in RA patients receiving cDMARD treatment compared to those of the control group. Also, eicosadienoic acid, myristoleic acid and capric acid levels were significantly lower in the patient groups compared to those in the control group.

Conclusion: The drugs used in the treatment of RA had no effect on the fatty acid levels whereas had effects on the mRNA and protein levels of the target cytokines.

Citing Articles

Investigating the therapeutic potential of sinomenine in rheumatoid arthritis: anti-inflammatory, antioxidant, and immunomodulatory mechanisms.

Li J, Cao J, Chen Q, Liu D, Li R Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(6):3945-3958.

PMID: 37991542 DOI: 10.1007/s00210-023-02810-0.

Metabolic Effects of Anti-TNF-α Treatment in Rheumatoid Arthritis.

Macakova K, Tekelova M, Mlynarikova V, Sebekova K, Vlkova B, Celec P Diseases. 2023; 11(4).

PMID: 37987275 PMC: 10660495. DOI: 10.3390/diseases11040164.

Exploring the molecular mechanism of Sishen Decoction in the treatment of rheumatoid arthritis.

Zheng J, Zhao Y, Qi Q, Gao M, Yu J Ann Transl Med. 2022; 10(18):977.

PMID: 36267726 PMC: 9577749. DOI: 10.21037/atm-22-3888.

References

Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M . The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014; 73(7):1323-30. DOI: 10.1136/annrheumdis-2013-204763. View

Quinonez-Flores C, Gonzalez-Chavez S, Del Rio Najera D, Pacheco-Tena C . Oxidative Stress Relevance in the Pathogenesis of the Rheumatoid Arthritis: A Systematic Review. Biomed Res Int. 2016; 2016:6097417. PMC: 4906181. DOI: 10.1155/2016/6097417. View

Aletaha D, Neogi T, Silman A, Funovits J, Felson D, Bingham 3rd C . 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62(9):2569-81. DOI: 10.1002/art.27584. View

Rio D, Ares Jr M, Hannon G, Nilsen T . Purification of RNA using TRIzol (TRI reagent). Cold Spring Harb Protoc. 2010; 2010(6):pdb.prot5439. DOI: 10.1101/pdb.prot5439. View

Hruz T, Wyss M, Docquier M, Pfaffl M, Masanetz S, Borghi L . RefGenes: identification of reliable and condition specific reference genes for RT-qPCR data normalization. BMC Genomics. 2011; 12:156. PMC: 3072958. DOI: 10.1186/1471-2164-12-156. View

Vors C, Allaire J, Marin J, Lepine M, Charest A, Tchernof A . Inflammatory gene expression in whole blood cells after EPA vs. DHA supplementation: Results from the ComparED study. Atherosclerosis. 2017; 257:116-122. DOI: 10.1016/j.atherosclerosis.2017.01.025. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Noack M, Miossec P . Selected cytokine pathways in rheumatoid arthritis. Semin Immunopathol. 2017; 39(4):365-383. DOI: 10.1007/s00281-017-0619-z. View

Radner H, Aletaha D . Anti-TNF in rheumatoid arthritis: an overview. Wien Med Wochenschr. 2015; 165(1-2):3-9. DOI: 10.1007/s10354-015-0344-y. View

10.

Musacchio E, Valvason C, Botsios C, Ostuni F, Furlan A, Ramonda R . The tumor necrosis factor-{alpha}-blocking agent infliximab inhibits interleukin 1beta (IL-1beta) and IL-6 gene expression in human osteoblastic cells. J Rheumatol. 2009; 36(8):1575-9. DOI: 10.3899/jrheum.081321. View

11.

Wielinska J, Dratwa M, Swierkot J, Korman L, Iwaszko M, Wysoczanska B . Interleukin 6 gene polymorphism is associated with protein serum level and disease activity in Polish patients with rheumatoid arthritis. HLA. 2018; 92 Suppl 2:38-41. DOI: 10.1111/tan.13355. View

12.

Smolen J, Emery P, Fleischmann R, van Vollenhoven R, Pavelka K, Durez P . Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet. 2013; 383(9914):321-32. DOI: 10.1016/S0140-6736(13)61751-1. View

13.

Detert J, Bastian H, Listing J, Weiss A, Wassenberg S, Liebhaber A . Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis. 2012; 72(6):844-50. DOI: 10.1136/annrheumdis-2012-201612. View

14.

Chen Z, Bozec A, Ramming A, Schett G . Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis. Nat Rev Rheumatol. 2018; 15(1):9-17. DOI: 10.1038/s41584-018-0109-2. View

15.

Qu C, Hou Y, Bi Y, Han Q, Jiao C, Zou Q . Diagnostic values of serum IL-10 and IL-17 in rheumatoid arthritis and their correlation with serum 14-3-3η protein. Eur Rev Med Pharmacol Sci. 2019; 23(5):1899-1906. DOI: 10.26355/eurrev_201903_17227. View

16.

Osiri M, Wongpiyabovorn J, Sattayasomboon Y, Thammacharoenrach N . Inflammatory cytokine levels, disease activity, and function of patients with rheumatoid arthritis treated with combined conventional disease-modifying antirheumatic drugs or biologics. Clin Rheumatol. 2016; 35(7):1673-81. DOI: 10.1007/s10067-016-3306-x. View

17.

Hernandez-Bello J, Oregon-Romero E, Vazquez-Villamar M, Garcia-Arellano S, Valle Y, Padilla-Gutierrez J . Aberrant expression of interleukin-10 in rheumatoid arthritis: Relationship with IL10 haplotypes and autoantibodies. Cytokine. 2017; 95:88-96. DOI: 10.1016/j.cyto.2017.02.022. View

18.

Farazi T, Spitzer J, Morozov P, Tuschl T . miRNAs in human cancer. J Pathol. 2010; 223(2):102-15. PMC: 3069496. DOI: 10.1002/path.2806. View

19.

Friedman J, Jones P . MicroRNAs: critical mediators of differentiation, development and disease. Swiss Med Wkly. 2009; 139(33-34):466-72. PMC: 2854010. DOI: 10.4414/smw.2009.12794. View

20.

Liu Y, Chen Q, Song Y, Lai L, Wang J, Yu H . MicroRNA-98 negatively regulates IL-10 production and endotoxin tolerance in macrophages after LPS stimulation. FEBS Lett. 2011; 585(12):1963-8. DOI: 10.1016/j.febslet.2011.05.029. View